Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)

The discovery and development of novel treatments that harness the patient's immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses ar...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of translational medicine 2023-07, Vol.21 (1), p.488-488
Main Authors:	Ascierto, Paolo A, Avallone, Antonio, Bifulco, Carlo, Bracarda, Sergio, Brody, Joshua D, Emens, Leisha A, Ferris, Robert L, Formenti, Silvia C, Hamid, Omid, Johnson, Douglas B, Kirchhoff, Tomas, Klebanoff, Christopher A, Lesinski, Gregory B, Monette, Anne, Neyns, Bart, Odunsi, Kunle, Paulos, Chrystal M, Powell, Jr, Daniel J, Rezvani, Katayoun, Segal, Brahm H, Singh, Nathan, Sullivan, Ryan J, Fox, Bernard A, Puzanov, Igor
Format:	Article
Language:	eng
Subjects:	Analysis Biomarkers Cancer vaccines Care and treatment Cellular therapy Checkpoint inhibitors Combination therapy Diagnosis Dosage and administration Humans Immune response Immunotherapy Immunotherapy, Adoptive Italy Meeting Report Melanoma Melanoma - pathology Patient outcomes Tumor Microenvironment Vaccine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The discovery and development of novel treatments that harness the patient's immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. The use of cell therapies, drivers of immune response, and trends in immunotherapy were the focus of the Immunotherapy Bridge (November 30th-December 1st, 2022), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer.
ISSN:	1479-5876 1479-5876